# US 2026/0062483 A1 · Treatment paradigm for an anti-cd19 antibody therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062483 A1
- Document ID: US20260062483A1
- Status: Published application
- Kind: A1
- Application number: 19/303,673
- Filed: 2025-08-19
- Published: 2026-03-05
- Earliest claimed: 2021-12-22
- Assignees: Incyte Corporation
- Applicants: Incyte Corporation
- Inventors: Stefan Härtle; Frank Striebel
- Web page: https://patentgrep.com/patent/US20260062483A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61P 35/00: Antineoplastic agents
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides anti-CD19 antibodies for use in the treatment of various cancers. The anti-CD19 antibody is administered to cancer patients in a specific dose or dosing regimen.

## Claims

### Claim 1

An anti-CD19 antibody, for use in the treatment of a cancer wherein said anti-CD19 antibody is administered at a dose of at least 24 mg/kg.

### Claim at position 2

-23. (canceled)

### Claim 24

A method of treating a cancer in a human subject in need thereof, the method comprising administering to the human subject an anti-CD19 antibody, wherein the anti-CD19 antibody is administered at a dose of at least 24 mg/kg.

### Claim 25

(canceled)

### Claim 26 (depends on 24)

The method of claim 24, wherein the anti-CD19 antibody comprises a heavy chain variable region comprising an HCDR1 region of SYVMH (SEQ ID NO: 1), an HCDR2 region of NPYNDG (SEQ ID NO: 2), and an HCDR3 region of GTYYYGTRVFDY (SEQ ID NO: 3) and a light chain variable region comprising an LCDR1 region of RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of MQHLEYPIT (SEQ ID NO: 6).

### Claim 27 (depends on 24)

The method of claim 24, wherein the anti-CD19 antibody comprises a heavy chain variable region of
(SEQ ID NO: 7)
EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIG
YINPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCAR
GTYYYGTRVFDYWGQGTLVTVSS
and a light chain variable region of
(SEQ ID NO: 8)
DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSP
QLLIYRMSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLE
YPITFGAGTKLEIK.

### Claim 28 (depends on 24)

The method of claim 24, wherein the anti-CD19 antibody comprises an Fc domain comprising an amino acid substitution at position S239 and/or 1332, wherein the numbering is according to the EU index as in Kabat.

### Claim 29 (depends on 24)

The method of claim 24, wherein the anti-CD19 antibody comprises an Fc domain comprising an S239D amino acid substitution and an 1332E amino acid substitution, wherein the numbering is according to the EU index as in Kabat.

### Claim 30 (depends on 24)

The method of claim 24, wherein the anti-CD19 antibody comprises a heavy chain constant region of
(SEQ ID NO: 9)
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG
VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV
EPKSCDKTHTCPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVV
DVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDW
LNGKEYKCKVSNKALPAPEEKTISKTKGQPREPQVYTLPPSREEMTKNQ
VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLT
VDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
and a light chain constant region of
(SEQ ID NO: 10)
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQS
GNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPV
TKSFNRGEC.

### Claim 31 (depends on 24)

The method of claim 24, wherein the anti-CD19 antibody comprises a heavy chain region of
(SEQ ID NO: 11)
EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIG
YINPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCAR
GTYYYGTRVFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALG
CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPDVF
LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTK
PREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKALPAPEEKTISKT
KGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE
NNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT
QKSLSLSPGK
and a light chain region of
(SEQ ID NO: 12)
DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSP
QLLIYRMSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLE
YPITFGAGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPR
EAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKV
YACEVTHQGLSSPVTKSFNRGEC.

### Claim 32 (depends on 24)

The method of claim 24, wherein the anti-CD19 antibody is administered intravenously, by intravenous infusion or subcutaneously.

### Claim 33 (depends on 24)

The method of claim 24, wherein said dose reduces the dosing frequency from once weekly to at least once every two weeks.

### Claim 34 (depends on 24)

The method of claim 24, wherein the cancer is a hematological malignancy.

### Claim 35 (depends on 24)

The method of claim 24, wherein the cancer is a lymphoma or a leukemia.

### Claim 36 (depends on 24)

The method of claim 24, wherein the cancer is non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) or acute lymphoblastic leukemia (ALL).

### Claim 37 (depends on 24)

The method of claim 24, wherein the cancer is Diffuse large B-cell lymphoma (DLBCL) or relapsed or refractory Diffuse large B-cell lymphoma (r/r DLBCL).

### Claim 38 (depends on 24)

The method of claim 24, wherein the anti-CD19 antibody is administered once a week, once every two weeks or once every four weeks.

### Claim 39 (depends on 24)

The method of claim 24, wherein the anti-CD19 antibody is administered at a dose in the range of between 24 mg/kg to 30 mg/kg.

### Claim 40 (depends on 24)

The method of claim 24, wherein the anti-CD19 antibody is administered at a dose of 24 mg/kg.

### Claim 41 (depends on 24)

The method of claim 24, wherein the anti-CD19 antibody is administered at a dose of 30 mg/kg.

### Claim 42 (depends on 24)

The method of claim 24, wherein the anti-CD19 antibody is administered in 28-day cycles, wherein on: a) days 1, 4 and 9 of the first cycle, a dose of 12 mg/kg is administered and on day 15 of the first cycle a dose of at least 24 mg/kg is administered; b) days 1 and 15 of cycles 2-3, a dose of at least 24 mg/kg is administered; and c) day 1 of further subsequent cycles, a dose of at least 24 mg/kg is administered.

### Claim 43 (depends on 24)

The method of claim 24, wherein the anti-CD19 antibody is administered in 28-day cycles, wherein on: a) days 1, 4 and 9 of the first cycle, a dose of 12 mg/kg is administered and on day 15 of the first cycle a dose in the range of between 24 mg/kg to 30 mg/kg is administered; b) days 1 and 15 of cycles 2-3, a dose in the range of between 24 mg/kg to 30 mg/kg is administered; and c) day 1 of further subsequent cycles, a dose in the range of between 24 mg/kg to 30 mg/kg is administered.

### Claim 44 (depends on 24)

The method of claim 24, wherein the anti-CD19 antibody is administered in 28-day cycles, wherein on: a) days 1, 4 and 9 of the first cycle, a dose of 12 mg/kg is administered and on day 15 of the first cycle a dose of 24 mg/kg is administered; b) days 1 and 15 of cycles 2-3, a dose of 24 mg/kg is administered; and c) day 1 of further subsequent cycles, a dose of 24 mg/kg is administered.

### Claim 45 (depends on 24)

The method of claim 24, wherein the anti-CD19 antibody is administered in 28-day cycles, wherein on: a) days 1, 4 and 9 of the first cycle, a dose of 12 mg/kg is administered and on day 15 of the first cycle a dose of 30 mg/kg is administered; b) days 1 and 15 of cycles 2-3, a dose of 30 mg/kg is administered; and c) day 1 of further subsequent cycles, a dose of 30 mg/kg is administered.

### Claim 46 (depends on 24)

The method of claim 24, wherein the anti-CD19 antibody is administered in combination with lenalidomide.

### Claim 47

A pharmaceutical composition comprising an anti-CD19 antibody and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is capable of delivering a dose of at least 24 mg/kg of the anti-CD19 antibody when administered to a subject.
